Abbott Laboratories (NYSE:ABT) has been successful in persuading a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. The parents lacked standing to sue as they did not show which Abbott products or lots were contaminated, or that their children experienced symptoms. The judge also narrowed but did not dismiss two related lawsuits against Abbott. The first lawsuit involves 28 plaintiffs bringing personal injury claims alleging that Abbott’s formula caused salmonella contamination, bacterial meningitis and other health problems. The second lawsuit by eight plaintiffs alleged that Similac products contained heavy metals and were manufactured in unsanitary decisions. Abbott did not immediately respond to requests for comment. The litigation follows Abbott’s February 2022 closure of a baby formula plant in Sturgis, Michigan and subsequent recalls, which together caused a nationwide shortage of formula. The plaintiffs are currently reviewing their next steps.
Categories